Sanofi will acquire exclusive rights to aficamten for treating hypertrophic cardiomyopathy in Greater China from Corxel Pharmaceuticals.
Quiver AI Summary
Cytokinetics, Inc. announced that Sanofi will acquire exclusive rights to aficamten from Corxel Pharmaceuticals for the treatment of hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten, a next-generation cardiac myosin inhibitor, is designed to target both obstructive and non-obstructive forms of HCM. Following Corxel's 2020 acquisition of rights from Cytokinetics, aficamten received Breakthrough Therapy Designation from China's drug regulatory authority and is currently under priority review. Sanofi's acquisition will result in Cytokinetics receiving potential milestone payments up to $150 million and royalties from future sales in the region. Cytokinetics plans to leverage Sanofi's expertise in cardiovascular treatments to broaden aficamten's access for patients with HCM in Greater China.
Potential Positives
- Sanofi's acquisition of exclusive rights to develop aficamten in Greater China presents a significant opportunity for Cytokinetics to expand its market presence and increase revenue potential through milestone payments and royalties.
- Receiving Breakthrough Therapy Designation and Priority Review status for aficamten from regulatory agencies in China highlights the drug's potential therapeutic value and positions Cytokinetics favorably within the industry.
- The transition of rights to a prominent company like Sanofi suggests strong confidence in the viability and demand for aficamten, potentially enhancing its reputation and credibility in the biopharmaceutical market.
- Cytokinetics has the opportunity to collaborate with Sanofi, leveraging their cardiovascular expertise to accelerate the development and commercialization processes for aficamten, ultimately benefiting patient access to this treatment.
Potential Negatives
- The disclosure that Sanofi is acquiring exclusive rights to develop and commercialize aficamten may indicate that Cytokinetics is losing control over a significant asset in a key market, potentially impacting its future revenue from this drug.
- The announcement includes the term "undisclosed amount" regarding the acquisition, which raises concerns about the potential financial implications for Cytokinetics if the terms are unfavorable.
- Cytokinetics' eligibility for milestone payments and royalties could be seen as insufficient compensation given that they will no longer have direct involvement in the commercialization process in Greater China, possibly limiting revenue growth opportunities.
FAQ
What is Aficamten used for?
Aficamten is a cardiac myosin inhibitor being developed for treating obstructive and non-obstructive hypertrophic cardiomyopathy (HCM).
Who is acquiring Aficamten rights in Greater China?
Sanofi will acquire exclusive rights to develop and commercialize Aficamten in Greater China from Corxel Pharmaceuticals.
What designation has Aficamten received from regulatory agencies?
Aficamten received Breakthrough Therapy Designation from the U.S. FDA for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
How much can Cytokinetics potentially earn from this agreement?
Cytokinetics may receive up to $150 million in milestone payments and royalties from future sales of Aficamten.
What is the clinical significance of Aficamten?
Aficamten aims to improve exercise capacity and relieve symptoms in HCM patients, addressing myocardial hypercontractility.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CYTK Insider Trading Activity
$CYTK insiders have traded $CYTK stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- WENDALL WIERENGA has traded it 3 times. They made 0 purchases and 3 sales, selling 5,936 shares.
- JOHN T HENDERSON sold 1,780 shares.
- FADY IBRAHAM MALIK (EVP Research & Development) has traded it 26 times. They made 0 purchases and 26 sales, selling 94,026 shares.
- ROBERT I BLUM (President & CEO) has traded it 11 times. They made 0 purchases and 11 sales, selling 81,000 shares.
- B LYNNE PARSHALL has traded it 6 times. They made 0 purchases and 6 sales, selling 30,000 shares.
- ROBERT ARTHUR HARRINGTON sold 253 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CYTK Hedge Fund Activity
We have seen 193 institutional investors add shares of $CYTK stock to their portfolio, and 200 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DARWIN GLOBAL MANAGEMENT, LTD. removed 4,575,558 shares (-100.0%) from their portfolio in Q3 2024
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,551,310 shares (+19.1%) to their portfolio in Q3 2024
- PRICE T ROWE ASSOCIATES INC /MD/ added 806,602 shares (+34.2%) to their portfolio in Q3 2024
- BLACKROCK, INC. added 580,060 shares (+4.0%) to their portfolio in Q3 2024
- VESTAL POINT CAPITAL, LP removed 575,000 shares (-27.7%) from their portfolio in Q3 2024
- FMR LLC added 571,126 shares (+5.0%) to their portfolio in Q3 2024
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 542,009 shares (-97.6%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize
aficamten
from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China.
Aficamten
is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM.
In 2020, CORXEL (formerly Ji Xing) acquired the rights to develop and commercialize
aficamten
in Greater China (including the Chinese mainland, Hong Kong SAR and Macau SAR, and Taiwan) from Cytokinetics in accordance with Cytokinetics’ global registration programs.
Aficamten
received Breakthrough Therapy Designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from The Center for Drug Evaluation of the China National Medical Products Administration which recently accepted the New Drug Application for
aficamten
tablets for the treatment of oHCM for Priority Review.
Sanofi will now acquire CORXEL’s rights relating to
aficamten
in Greater China for an undisclosed amount. Cytokinetics remains eligible to receive up to $150 million in development and commercial milestone payments from Sanofi as well as royalties in the low-to-high teens on future sales of
aficamten
in Greater China. Cytokinetics is now also eligible to receive additional undisclosed payments in connection with the execution of the agreement between Sanofi and CORXEL.
“We have enjoyed a productive collaboration with CORXEL and appreciate all they have done to advance
aficamten
in Greater China,” said Robert I. Blum, Cytokinetics’ President and CEO. “We now look forward to partnering with Sanofi with shared objective to leverage their cardiovascular expertise and expand the reach of
aficamten
to patients suffering from HCM throughout Greater China.”
About
Aficamten
Aficamten
is an investigational selective, small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention to therapeutic index and pharmacokinetic properties and as may translate into next-in-class potential in clinical development.
Aficamten
was designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently suppress the myocardial hypercontractility that is associated with hypertrophic cardiomyopathy (HCM). In preclinical models,
aficamten
reduced myocardial contractility by binding directly to cardiac myosin at a distinct and selective allosteric binding site, thereby preventing myosin from entering a force producing state.
The development program for
aficamten
is assessing its potential as a treatment that improves exercise capacity and relieves symptoms in patients with HCM as well as its potential long-term effects on cardiac structure and function
. Aficamten
was evaluated in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of
Aficamten
in HCM), a positive pivotal Phase 3 clinical trial in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Aficamten
received Breakthrough Therapy Designation for the treatment of symptomatic obstructive HCM from the U.S. Food & Drug Administration (FDA). The FDA recently accepted the company’s New Drug Application (NDA) for aficamten, for the treatment of obstructive hypertrophic cardiomyopathy and assigned the NDA a Prescription Drug User Fee Act target action date of September 26, 2025. Cytokinetics also recently submitted a Marketing Authorization Application for
aficamten
to the European Medicines Agency.
Aficamten
is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of
aficamten
as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of
aficamten
in patients with non-obstructive HCM, and CEDAR-HCM, a clinical trial of
aficamten
in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of
aficamten
in patients with HCM.
About Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller and stiffer, and thus the ventricle becomes less able to relax and fill with blood. This ultimately limits the heart’s pumping function, resulting in reduced exercise capacity and symptoms including chest pain, dizziness, shortness of breath, or fainting during physical activity. HCM is the most common monogenic inherited cardiovascular disorder, with approximately 280,000 patients diagnosed, however, there are an estimated 400,000-800,000 additional patients who remain undiagnosed in the U.S.
1,2,3
Two-thirds of patients with HCM have obstructive HCM, in which the thickening of the cardiac muscle leads to left ventricular outflow tract obstruction, while one-third have non-obstructive HCM, in which blood flow isn’t impacted, but the heart muscle is still thickened. People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.
4
People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.
5
A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is readying for the potential commercialization of
aficamten,
a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM).
Aficamten
is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing
omecamtiv mecarbil
, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from
aficamten,
for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit
www.cytokinetics.com
and follow us on
X
,
LinkedIn
,
Facebook
and
YouTube
.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission, particularly under the caption “Risk Factors” in Cytokinetics’ latest Quarterly Report on Form 10-Q.
CYTOKINETICS
®
and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
References
CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575
Symphony Health 2016-2021 Patient Claims Data DoF;
Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.
Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.
Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
